Trevi Therapeutics Q3 2023 Gaap EPS $(0.08) Beats $(0.09) Estimate
Portfolio Pulse from saritha@benzinga.com
Trevi Therapeutics reported Q3 2023 GAAP EPS of $(0.08), beating the analyst consensus estimate of $(0.09) by 11.11%. This represents a 33.33% increase over losses from the same period last year.
November 09, 2023 | 9:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Trevi Therapeutics' Q3 2023 earnings beat estimates, showing an improvement from last year's losses.
Trevi Therapeutics reported better than expected earnings for Q3 2023, which is a positive signal for investors. The company's losses have also decreased compared to the same period last year, indicating an improvement in its financial performance. This could potentially lead to a short-term increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100